https://www.i-rna.ca/news/new-peer-reviewed-study-on-lncrna-targeting-eyedrop-approach-for-potential-diabetic-retinopathy-therapy 2026-01-26 https://www.i-rna.ca/news/i-rna-corporation-kicks-off-2026-with-strategic-industry-engagements-at-obio%C2%AE-investment-summit-and-attd-2026 2026-01-26 https://www.i-rna.ca/news/i-rna-corporation-receives-dual-awards-at-effervescence-2025 2026-01-26 https://www.i-rna.ca/news/i-rna-corporation-partners-with-jlabs-%40-toronto-to-drive-innovation-in-diabetic-retinopathy-therapy 2026-01-26 https://www.i-rna.ca/news/i-rna-corporation-launches-with-pioneering-rna-therapies-and-secures-key-intellectual-property-transfer 2026-01-26 https://www.i-rna.ca/news/i-rna-corporation-joins-johnson-%26-johnson-innovation---jlabs-as-a-new-resident-company-in-toronto! 2026-01-26 https://www.i-rna.ca/news/dr.-chakrabarti-presents-data-on-its-rna-based-treatments-of-diabetic-retinopathy-at-iser-in-argentina 2026-01-26